Approval · Notice of Compliance 29342 · 2022
RELPAX: Notice of Compliance 29342
Issued October 26, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29342
- Date
- October 26, 2022
- Company
- Upjohn Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfill commitment made during market authorization transfer from Pfizer Canada ULC to Upjohn Canada ULC: Adding Lot and Expiry date on each cell of blister foil label; and Update inner/outer labels and Package Insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RELPAX | Not yet assigned | — |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB